Evofem Biosciences Inc (EVFM)
Evofem Biosciences is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health, including woman-controlled contraception and protection from certain sexually transmitted infections. Co.'s commercial product, Phexxi, is the U.S. Food and Drug Administration (FDA)-approved, hormone-free, woman-controlled, prescription contraceptive gel for women. Co. is evaluating Phexxi for two potential new indications: the prevention of chlamydia and the prevention of gonorrhea in women. The FDA has designated Phexxi, using the investigational name EVO100, as a Qualified Infectious Disease Product.
|
Free EVFM Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Buy (3.17 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: EVFM Stock Forecast Based on Zacks ABR data; powered by Xignite |